Markets traded volatile on Thursday and ended almost unchanged amid favourable cues. Despite the favourable cues, analysts say the Nifty continues to face a lack of momentum on the upside due to the resistance posed by key moving averages (100 and 200 DEMA). A decisive close above 24,200 remains critical for bulls to maintain firm control and approach the 200-day EMA near the 24,500 level.
In today's trade, shares of Waaree Energies, Kotak Bank, HDFC Bank, Strides Pharma, Persistent Systems among others will be in focus due to various news developments.
With India's electric vehicle adoption crossing the 'early adopters' phase, Tata Motors Passenger Vehicles is turning to majority of customers to drive EV adoption with four new products and over ten refreshes lined up for launch by FY31 to sustain its leadership position.
Waaree Energies said on Sunday that a US investigation did not find that the company had exported solar panels made with Chinese solar cells, and that the probe was limited to a narrow set of historical import entries with no impact on its ongoing US operations.
Former HDFC Bank chairman Atanu Chakraborty has called into question the need for the lender's external legal review into the circumstances surrounding his resignation, describing the exercise as unnecessary and maintaining that he declined to participate because the bank never shared the scope or legal basis of the investigation.
Strides Pharma Science Ltd on Saturday announced divestment of majority stake in its wholly-owned arm Pivot Path for Rs 100 crore to a consortium of investors led by Ascent Capital, along with co-investor Vintage.
Adani Green arm operationalised solar power project of 150 MW at Khavda, Gujarat. With this project, the company achieved total operational renewable generation capacity of 19,985.8 MW & total operational BESS capacity of 3,366 MWh.
PTC Industries Board has approved raising funds up to Rs 1,800 crore via QIP, preferential issue, and other means. The Board has also approved loans, guarantees, securities & investments of up to Rs 2,000 crore. Further, the company cleared increasing borrowing limit to Rs 600 crore from Rs 350 crore.
The company has entered into a long-term strategic services agreement with a global technology leader headquartered in the United States. The agreement is aimed at expanding the company’s presence across North America, Europe, and Asia Pacific and encompasses end to end operations, management, and support of a portfolio of enterprise Cloud services. The arrangement is expected to strengthen the Company’s business capabilities and enable both parties to derive long-term strategic benefits.
Alembic Pharma received USFDA final approval for Oseltamivir oral suspension. Oseltamivir Oral suspension is used to treat and prevent influenza A and B.
